Cargando…

Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States

This study assessed the occurrence of indicators for suboptimal biologic therapy among ulcerative colitis (UC) and Crohn’s disease (CD) patients over time in the United States (US). Data from a large US claims database (2005–2013) were used to retrospectively identify patients with diagnosed with ei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Haridarshan, Lissoos, Trevor, Rubin, David T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398513/ https://www.ncbi.nlm.nih.gov/pubmed/28426675 http://dx.doi.org/10.1371/journal.pone.0175099

Ejemplares similares

Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States
por: Siegel, Corey A., et al.
Publicado: (2020)

A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
por: Ungaro, Ryan, et al.
Publicado: (2019)

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
por: Hibi, Toshifumi, et al.
Publicado: (2021)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Prevalence and screening for anaemia in mild to moderate Crohn's disease and ulcerative colitis in the United States, 2010–2014
por: Akhuemonkhan, Eboselume, et al.
Publicado: (2017)

Increasing thirty-day readmissions of Crohn’s disease and ulcerative colitis in the United States: A national dilemma
por: Dahiya, Dushyant Singh, et al.
Publicado: (2022)

Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany
por: Bokemeyer, Bernd, et al.
Publicado: (2023)

Patient and physician preferences for ulcerative colitis treatments in the United States
por: Boeri, Marco, et al.
Publicado: (2019)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
por: Ooi, Choon Jin, et al.
Publicado: (2019)

Indicators of Suboptimal Treatment and Associated Healthcare Costs Among Patients With Crohn’s Disease Initiated on Biologic or Conventional Agents
por: Pilon, Dominic, et al.
Publicado: (2022)

Crohn's disease and ulcerative colitis Surgical management
por: Wilkinson, A J
Publicado: (1996)

Mucosal Barrier in Ulcerative Colitis and Crohn's Disease
por: Dorofeyev, A. E., et al.
Publicado: (2013)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Ulcerative Colitis and Crohn's Disease: Similarities and Distinctions
por: Sawyerr, Af M, et al.
Publicado: (1994)

Review of pregnancy in Crohn’s disease and ulcerative colitis
por: Laube, Robyn, et al.
Publicado: (2021)

Work-Related Productivity Loss and Associated Indirect Costs in Patients With Crohn’s Disease or Ulcerative Colitis in the United States
por: Ding, Zhijie, et al.
Publicado: (2022)

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2
por: Feagan, Brian G, et al.
Publicado: (2018)

Systems biology approach highlights mechanistic differences between Crohn’s disease and ulcerative colitis
por: Ruiz Castro, Pedro A., et al.
Publicado: (2021)

Expressing the Differences between Crohn Disease and Ulcerative Colitis
por: Wijmenga, Cisca
Publicado: (2005)

Carbohydrate Intake in the Etiology of Crohn's Disease and Ulcerative Colitis
por: Chan, Simon S. M., et al.
Publicado: (2014)

The Changing Prognosis of Ulcerative Colitis and Crohn Disease by Decades
por: Korelitz, Burton I, et al.
Publicado: (2021)

Diagnosis of Crohn’s disease and ulcerative colitis using the microbiome
por: Kang, Da-Yeon, et al.
Publicado: (2023)

Psychometric evaluation of the Urgency NRS as a new patient-reported outcome measure for patients with ulcerative colitis
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Plasma microRNA Profile Differentiates Crohn’s Colitis From Ulcerative Colitis
por: Netz, Uri, et al.
Publicado: (2018)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Identification of inadequate responders to advanced therapy among commercially-insured adult patients with Crohn’s disease and ulcerative colitis in the United States
por: Gibble, Theresa Hunter, et al.
Publicado: (2023)

Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data
por: Bokemeyer, Bernd, et al.
Publicado: (2022)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Gastritis Associated with Initially Pediatric Crohn's Disease and Ulcerative Colitis
por: Basturk, Ahmet, et al.
Publicado: (2018)

Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles
por: Nemeth, Zoltan H, et al.
Publicado: (2017)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Salivary Stress/Immunological Markers in Crohn’s Disease and Ulcerative Colitis
por: Finamore, Alberto, et al.
Publicado: (2020)

A comparison of diverticulitis in Crohn's disease versus ulcerative colitis
por: Persaud, Alana, et al.
Publicado: (2019)

Gut Microbiota and Metabolic Specificity in Ulcerative Colitis and Crohn's Disease
por: Sankarasubramanian, Jagadesan, et al.
Publicado: (2020)

Prevalence of endodontic infection in patients with Crohn´s disease and ulcerative colitis
por: Poyato-Borrego, Manuel, et al.
Publicado: (2021)

Differentially Expressed miRNAs in Ulcerative Colitis and Crohn’s Disease
por: Yarani, Reza, et al.
Publicado: (2022)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

Infliximab therapy for moderately severe Crohn’s disease and ulcerative colitis: a retrospective comparison over 6 years
por: Alzafiri, Raed, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h2d4l2t2iuragdta111hj6ojoe